血清IL-6水平检测在原发免疫性血小板减少症患者预后疗效评估的临床意义

The clinical significance of serum IL-6 level in evaluating the prognosis and efficacy of patients with primary immune thrombocytopenia

目的本研究旨在探索血清白介素6(IL-6)水平对初诊原发免疫性血小板减少症患者预后疗效的影响。方法回顾性分析70例符合原发免疫性血小板减少症诊断的初诊患者,收集患者的临床资料,并对血清IL-6水平、血小板计数、出血评分进行测定。根据血清IL-6测量结果,将患者分为低水平组(IL-6≤25 pg/mL)、中水平组(2535 pg/mL)。应用标准化治疗并随访3个月,收集并分析患者实验室检查、疗效评价等指标。采用多元Cox回归分析IL-6水平与患者预后指标的相关性。结果治疗前,不同IL-6水平组患者的血小板计数和出血评分差异无统计学意义(P>0.05)。治疗3个月后,IL-6高水平组的血小板计数更低,出血评分更高(P<0.05);IL-6低水平组的预后疗效最好(P<0.05)。患者的年龄、病程、治疗后的出血评分、血小板计数和疗效评价与IL-6水平呈相关关系(P<0.05)。结论本研究表明血清IL-6与原发免疫性血小板减少症患者的预后存在相关性,高IL-6水平可能提示原发免疫性血小板减少症预后较差。IL-6水平有望成为早期评估原发免疫性血小板减少症患者预后的潜在生物标志物,但仍需进一步的研究和验证。

Objective To explore the impact of interleukin-6(IL-6)levels and on the prognostic efficacy of primary immune thrombocytopenia(ITP)patients.Methods 70 patients diagnosed with ITP were retrospectively analyzed.The clinical data were collected,and the serum IL-6 levels,platelet counts and bleeding scores were detected.According to the levels of serum IL-6,the patients were divided into low level group(IL-6≤25 pg/mL),medium level group(25<IL-6≤35 pg/mL),and high level group(IL-6>35 pg/mL).The standardized treatment was used and all patients were followed up for three months.Laboratory tests and efficacy evaluations were analyzed.Multiple Cox regression analysis was used to analyze the correlation between IL-6 levels and patient prognosis indicators.Results Before treatment,there was no significant differences in platelet counts and bleeding scores among patients with different level of IL-6(P>0.05).After three months of treatment,the high IL-6 level group had lower platelet counts and higher bleeding scores(P<0.05),while the low IL-6 level group showed the best prognosis(P<0.05).The age,disease duration,post-treatment bleeding score,platelet count,efficacy evaluation were correlated with IL-6 levels(P<0.05).Conclusion This study suggests a correlation between IL-6 and the prognosis of ITP patients,and high IL-6 levels may potentially indicate poor prognosis of ITP.The level of IL-6 is expected to be a potential biomarker for early evaluation of ITP patient prognosis,but further research and validation are still needed.